Foghorn Therapeutics (FHTX) Return on Invested Capital (2023 - 2024)
Foghorn Therapeutics (FHTX) recorded quarterly Return on Invested Capital of 0.05% in Q3 2024, up 177.86% quarter-over-quarter from 0.02% in Q2 2024, and up 3.0% on a YoY basis from 0.05% in Q4 2023.
Foghorn Therapeutics (FHTX) Return on Invested Capital (2023 - 2024) Analysis & Trends
Foghorn Therapeutics' Return on Invested Capital history runs 2 years deep, the most recent figure standing at 0.05% for Q3 2024.
- In Q3 2024, Return on Invested Capital rose 3.0% year-over-year to 0.05%; the TTM figure through Sep 2024 stood at 0.05% (up 3.0% YoY), while the FY2023 annual figure was 0.03%, changed N/A from the prior year.
- Return on Invested Capital was 0.05% for Q3 2024 at Foghorn Therapeutics, up from 0.02% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.1% in Q1 2023 to a low of 0.01% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.01% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -0.01% |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -0.01% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 0.05% |
| Jun 30, 2024 | 0.02% |
| Mar 31, 2024 | 0.01% |
| Dec 31, 2023 | 0.02% |
| Sep 30, 2023 | 0.02% |
| Jun 30, 2023 | 0.03% |
| Mar 31, 2023 | 0.10% |